The disclosure provides methods of treating tauopathies (e.g. Alzheimer's disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia with Parkinsonism linked to chromosome 17, Pick's Disease, Progressive Supranuclear Palsy, Dementia Pugilistica, Down's Syndrome and others) by administering humanized antibodies. The disclosure also provides the anti-tau humanized antibodies that bind the N-terminal region of tau and also bind to pathological tau aggregates, conformational epitopes and peptides mimicking these epitopes (mimotopes).
